Infospectives - Pancreatic Cancer
14 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Infospectives
Scoop.it!

Pancreatic Cancer Still The Deadliest, With 74% Of Patients Dying Within The ... - Medical Daily

Pancreatic Cancer Still The Deadliest, With 74% Of Patients Dying Within The ... - Medical Daily | Infospectives - Pancreatic Cancer | Scoop.it
Medical Daily
Pancreatic Cancer Still The Deadliest, With 74% Of Patients Dying Within The ...
Medical Daily
In four decades, the long-term survival rate of pancreatic cancer has not improved.
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Eyes On Merapi: Early Symptoms and Signs of Pancreatic Cancer

Eyes On Merapi: Early Symptoms and Signs of Pancreatic Cancer | Infospectives - Pancreatic Cancer | Scoop.it
Early Childhood Education Online Colouring Pictures-to Print-and-Colour (Early Symptoms and Signs of Pancreatic Cancer - http://t.co/XpKHPWkNGQ)
more...
No comment yet.
Rescooped by Infospectives from Amazing Science
Scoop.it!

AACR: Cancer Immunotherapy On Its Way To The Clinic

AACR: Cancer Immunotherapy On Its Way To The Clinic | Infospectives - Pancreatic Cancer | Scoop.it
Cancer immunotherapy refers to treatments that can unleash the power of a patient’s immune system to fight his or her cancer.


It seems that hardly a week goes by without there being a report of new breakthroughs in cancer immunotherapy. At the start of 2014, the focus was on the decision of the editors of Science to choose cancer immunotherapy as Breakthrough of the Year for 2013. In February, researchers at Memorial Sloan Kettering Cancer Center in New York published a study showing that 14 of 16 adults with relapsed or refractory acute lymphoblastic leukemia (ALL) had a complete response after treatment with an investigational cancer immunotherapy. And so it has gone on. Most recently, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to another investigational cancer immunotherapy, CTL019, for the treatment of pediatric and adult patients with relapsed/refractory ALL.


The excitement surrounding cancer immunotherapy was evident June 18, when a Twitter chat titled “The Promise of Immunotherapy,” organized by the American Association for Cancer Research (AACR) in partnership with Time magazine, the Mayo Clinic Cancer Center, and the Cancer Research Institute, reached an estimated 1.3 million individuals. But what is cancer immunotherapy, how does it work, and why are people so excited about it?


Cancer immunotherapy, which was featured as a key advance in patient care in the AACR Cancer Progress Report 2013, refers to treatments that can unleash the power of a patient’s immune system to fight his or her cancer. Decades of research have provided us with immense scientific insight into the immune system and how it interacts with cancer cells. This is what is allowing us to design increasing numbers of anticancer therapies that harness the immune system in different ways. It is also what is underpinning the groundswell of clinical trials testing cancer immunotherapies that we have seen in the past few years.


One of the reasons cancer immunotherapies have generated such excitement is that some have yielded dramatic and long-lasting responses in a number of patients. For example, Andrew Messinger (a cancer survivor featured in the AACR Cancer Progress Report 2013), who has metastatic melanoma – a disease that has an overall five-year survival rate of just 16 percent – is continuing to benefit from the cancer immunotherapy ipilimumab (Yervoy) five years after his first dose.


Ipilimumab is an example of a type of cancer immunotherapy known as a checkpoint inhibitor. These cancer immunotherapies work by releasing the ‘brakes’ on immune cells called T cells, which are naturally capable of destroying cancer cells. The brake released by ipilimumab is called CTLA4.


As highlighted in the AACR Cancer Progress Report 2014, which will be released in mid-September, a number of investigational cancer immunotherapies target a second T-cell brake called PD-1. One of these, pembrolizumab, is under review at the FDA as a potential treatment for metastatic melanoma. Another, nivolumab, received regulatory approval as a treatment for unresectable melanoma in Japan in July. Promising early results among patients with a number of other types of cancer, including non-small cell lung cancer and non-Hodgkin lymphoma, have been reported for PD-1-targeted cancer immunotherapies, but the data need to be confirmed in larger cohorts.


Despite all the excitement surrounding cancer immunotherapies, ipilimumab is one of the few currently approved by the FDA - it was approved for the treatment of metastatic melanoma in March 2011. As a result, most cancer immunotherapies remain investigational treatments, meaning that they have not yet been approved by the FDA and are still in development.


Fortunately, researchers are continuing to uncover new information about how the immune system functions. Thus, we can expect to see novel immunotherapies and new ways to use those that we already have in the future. Some of the most promising research in this area will be discussed at the AACR special conference Tumor Immunology and Immunotherapy: A New Chapter, which is being held in Orlando, Florida, Dec. 1-4. This conference is being put together in part by the AACR’s Cancer Immunology Working Group, which helps provide a forum for immunologists and non-immunologists to meet, exchange knowledge and ideas, and discuss the present status and future promise of cancer immunology.


Via Stefanie Charles, Dr. Stefan Gruenwald
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

The Weird Link Between Mouth Bacteria And Pancreatic Cancer

The Weird Link Between Mouth Bacteria And Pancreatic Cancer | Infospectives - Pancreatic Cancer | Scoop.it
The claim: A new, potentially life-saving method of diagnosing pancreatic cancer could be on the horizon.
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Pancreatic Cancer Q&A hosted by the Ron Foley Foundation on April 11, 2013

A lecture series hosted by the nonprofit charity group, the Ron Foley Foundation, on pancreatic cancer. Doctors Michael Karasik and David Curtis provide answ...
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

He Got About 199 Rejection Letters And 1 'Maybe' But Still Managed ...

He Got About 199 Rejection Letters And 1 'Maybe' But Still Managed ... | Infospectives - Pancreatic Cancer | Scoop.it
When Jack was first trying to find a space to do his research on pancreatic cancer, many laboratories turned him down. No one believed that a mere teenager could come up with a better diagnostic test for the cancer than the one that's been ...
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Pancreatic cancer: Scunthorpe widow Maggie Watts prepares for crunch talks in ... - Scunthorpe Telegraph

Pancreatic cancer: Scunthorpe widow Maggie Watts prepares for crunch talks in ... - Scunthorpe Telegraph | Infospectives - Pancreatic Cancer | Scoop.it
Scunthorpe Telegraph
Pancreatic cancer: Scunthorpe widow Maggie Watts prepares for crunch talks in ...
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Several genetic risk markers for pancreatic cancer are identified - Oncology Nurse Advisor

Several genetic risk markers for pancreatic cancer are identified - Oncology Nurse Advisor | Infospectives - Pancreatic Cancer | Scoop.it
Several genetic risk markers for pancreatic cancer are identified Oncology Nurse Advisor A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the...
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer

Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer | Infospectives - Pancreatic Cancer | Scoop.it
Immunotherapy combo receives breakthrough designation for Pancreatic Cancer http://t.co/5YzasuuzQc #cancer #oncology #biotech #biopharma
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Pancreatic Cancer, Deadly & Ignored - Please Help Make That Change

18th July: Thanks to an amazing 106,392 government epetition signatures, a parliamentary debate has been scheduled to look into Pancreatic Cancer under-funding, diagnostic failings and poor treatment...

more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Progress Made on Worst Pancreatic Cancer Cases

Progress Made on Worst Pancreatic Cancer Cases | Infospectives - Pancreatic Cancer | Scoop.it
PHILADELPHIA | Just seven years from now, pancreatic cancer is projected to become this country's second-leading cancer killer, surpassed only by lung cancer and claiming 48,000 lives a year.
more...
No comment yet.
Scooped by Infospectives
Scoop.it!

Figuring out why drugs don't work on pancreatic cancer - Ars Technica

Figuring out why drugs don't work on pancreatic cancer - Ars Technica | Infospectives - Pancreatic Cancer | Scoop.it
Ars Technica
Figuring out why drugs don't work on pancreatic cancer
Ars Technica
Pancreatic cancer is one of the most lethal cancers, with the survival period after diagnosis being only four to six months.
more...
No comment yet.